hxdbzxy / iStockphoto.com
“We didn’t do these cases because we’re against IP rights, but what we saw is, if you pay very substantial amounts of money to people in order for them not to go onto the market, it’s a bit fishy.”
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at email@example.com
IP, competition, competition law, AIPPI 2017, European Commission, Roschier, Bond University, Wasserbauer IP Law, pay-for-delay, pharmaceuticals,